Canada markets open in 54 minutes

CytRx Corporation (CYTR)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.5400-0.0100 (-1.82%)
At close: 03:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.5500
Open0.5697
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's Range0.5250 - 0.5900
52 Week Range0.4700 - 5.0000
Volume134,313
Avg. Volume70,653
Market Cap20.941M
Beta (5Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)-0.1510
Earnings DateNov. 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada

    LOS ANGELES, November 30, 2021--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today issued a presentation on Centurion BioPharma Corporation's ("Centurion BioPharma") plans for a world-class cancer center in Las Vegas, Nevada. Centurion BioPharma is a private wholly-owned subsidiary that focuses on advancing the Company's proprietary, albumin bindin

  • Business Wire

    CytRx Comments on Quarterly Results and Recent Strategic Initiatives

    LOS ANGELES, November 12, 2021--CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the quarter ended September 30, 2021. In addition, CytRx recapped corporate developments as well as matters pertaining to its agreements with ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio") and Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme"). T

  • Business Wire

    CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada

    LOS ANGELES, November 09, 2021--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Centurion BioPharma Corporation ("Centurion BioPharma"), a private wholly owned subsidiary that focuses on advancing the Company’s proprietary, albumin binding ultra-high potency LADR™ (Linker-Activated Drug Release) oncology drug candidates, has been